I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Newest

Geely STARRAY EM-i Sets the New GUINNESS WORLD RECORDS™ Title in Australia
Promoting Management Improvement Through Cultural Integration China Southern Power Grid International's First "Cultural Integration Month" Was a Highlight
LTG is about to be listed on BiFinance, the world's most fully licensed exchange, aiming to usher in a new chapter for the Bitcoin Depin ecosystem through the Lightning Network.
China Southern Power Grid's First Overseas Distribution Network Loss Reduction Pilot Project—the South Cairo, Egypt Project—has Successfully Passed Acceptance

Links

I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

2024-08-27 I-Mab Biopharma HaiPress

ROCKVILLE,Md.,Aug. 26,2024 -- I-Mab (NASDAQ: IMAB),a US-based,global,clinical-stage biotech company,exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer,today announced that management will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10,2024.

H.C. Wainwright 26th Annual Global Investment Conference

Presentation Time

Tuesday,September 10at5:00 PM ET

Presenters

Sean Fu,PhD,Interim Chief Executive Officer (CEO)

Phillip Dennis,MD,Chief Medical Officer (CMO)

Webcast link

Here

Meetings

One-on-one and small group meetings:September 9 – 10,2024

Management

Participants

Sean Fu,Interim CEO

Joe Skelton,Chief Financial Officer (CFO)

Phillip Dennis,CMO

Tyler Ehler,Senior Director,Investor Relations

The webcast will also be available under "Event Calendar" onI-Mab'sIR website

athttps://ir.i-mabbiopharma.com/

For more information,please contact your H.C. Wainwright representative.

About I-Mab

I-Mab (NASDAQ: IMAB) is a US-based,exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville,Maryland. For more information,please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.

For more information,please contact:

Tyler Ehler

Senior Director,Investor Relations

IR@imabbio.com

Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.